Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 3/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074893 | 1.00 | FUCA1 (0.38) | FUCA1SLC1A2ARG1ARG2GLA | |
| SCHEMBL976100 | 0.86 | ARG1 (0.46) | FUCA1SLC1A2ARG1ARG2GLA | |
| SCHEMBL12943747 | 0.83 | SLC1A2 (0.37) | SLC1A2ARG1ARG2TDP1 | |
| SCHEMBL1056439 | 0.72 | SLC1A2 (0.37) | SLC1A2ARG1ARG2 | |
| SCHEMBL942836 | 0.72 | SLC1A2 (0.37) | SLC1A2ARG1ARG2 | |
| SCHEMBL15121803 | 0.72 | SLC1A2 (0.37) | SLC1A2ARG1ARG2 | |
| SCHEMBL15121802 | 0.72 | SLC1A2 (0.37) | SLC1A2ARG1ARG2 | |
| SCHEMBL1022685 | 0.72 | SLC1A2 (0.37) | SLC1A2ARG1ARG2 | |
| SCHEMBL31345184 | 0.72 | — | — | |
| SCHEMBL1866565 | 0.68 | FUCA1 (0.40) | FUCA1GLAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448935-B1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2448946-B1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| EP-2448946-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | Novartis AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| EP-2448935-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | Novartis AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011000855-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| WO-2011000905-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000905-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | PIK3C3, PRKACA, UACA | FUCA1 2125/4885SLC1A2 3023/4885ARG1 631/4885 |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | UCK2, ULK3, ULK2 | FUCA1 1324/4885SLC1A2 2040/4885ARG1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.